SCHEMBL6420729

SCHEMBL6420729

OS1(O)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2454966 0.84
SCHEMBL2590771 0.65
SCHEMBL23866558 0.56
SCHEMBL256748 0.56
SCHEMBL7050307 0.50
SCHEMBL28393922 0.50
Cyclohexane SCHEMBL27713852 0.50
Cyclohexane SCHEMBL27992338 0.50
Cyclopropane SCHEMBL6702170 0.50
SCHEMBL28541358 0.47

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4628077-A2 LONG-ACTING SPIRO-ISOXAZOLINE FORMULATIONS Zoetis Services LLC (US) 2025-10-08 EP claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-20220016113-A1 ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA BAYER AKTIENGESELLSCHAFT (DE) 2022-01-20 US claimed
EP-3883933-A1 a2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2021-09-29 EP claimed
US-20200230136-A1 SELECTIVE ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS ALONE, OR IN COMBINATION WITH CHYMASE INHIBITORS FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PERIPHERAL ARTERY DISEASES (PAD) BAYER AKTIENGESELLSCHAFT (DE) 2020-07-23 US claimed
EP-3615031-A1 SELECTIVE ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS ALONE, OR IN COMBINATION WITH CHYMASE INHIBITORS FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PERIPHERAL ARTERY DISEASES (PAD) Bayer Aktiengesellschaft (DE) 2020-03-04 EP claimed
WO-2018197333-A1 SELECTIVE ADRENORECEPTOR ALPHA2C RECEPTOR ANTAGONISTS ALONE, OR IN COMBINATION WITH CHYMASE INHIBITORS FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF PERIPHERAL ARTERY DISEASES (PAD) BAYER AKTIENGESELLSCHAFT (DE) 2018-11-01 WO claimed
EP-3083592-B1 SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES AND THEIR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS Bayer Pharma AG (DE) 2018-06-27 EP claimed
US-9944621-B2 Substituted piperidinyl tetrahydroquinolines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-04-17 US claimed
US-9624198-B2 Substituted piperidinyltetrahydroquinolines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-04-18 US claimed
EP-3083592-A2 SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES AND THEIR USE AS ALPHA-2C ADRENORECEPTOR ANTAGONISTS Bayer Pharma Aktiengesellschaft (DE) 2016-10-26 EP claimed
EP-3083593-A1 SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES Bayer Pharma Aktiengesellschaft (DE) 2016-10-26 EP claimed
US-20160304491-A1 SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-20 US claimed
US-20160235720-A1 Long-Acting Spiro-Isoxazoline Formulations ZOETIS SERVICES LLC 2016-08-18 US claimed
EP-3052080-A1 LONG-ACTING SPIRO-ISOXAZOLINE FORMULATIONS Zoetis Services LLC (US) 2016-08-10 EP claimed
EP-2999339-A1 LONG-ACTING SPIRO-ISOXAZOLINE ANTIPARASITIC COMPOSITIONS Zoetis Services LLC (US) 2016-03-30 EP claimed
US-20160081986-A1 LONG-ACTING SPIRO-ISOXAZOLINE ANTIPARASITIC COMPOSITIONS ZOETIS SERVICES LLC (US) 2016-03-24 US claimed
WO-2015091417-A1 SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 WO claimed
WO-2015091414-A2 SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 WO claimed
WO-2015048371-A1 LONG-ACTING SPIRO-ISOXAZOLINE FORMULATIONS ZOETIS LLC (US) 2015-04-02 WO claimed